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Abstract
Influenza infection is usually a self-limiting and suddenly life-threatening disease. Sea-
sonal influenza causes severe clinical symptoms and almost subsides within 7 days in
patients without severe illness, following no complications of pneumonia and encephali-
tis. Influenza A (H1N1) pdm09 brought the disaster including many deaths. We cannot
make differential diagnosis between seasonal and pandemic influenza adequately in a
pre-pandemic state. Seasonal influenza displaces suddenly pandemic, and we necessarily
establish a standard treatment for influenza viral infection in routine work. If antiviral
therapy would not be effective for patients with influenza viruses in an early period of
illness, further investigations would be proceeded concerning three points: mutations of
influenza viruses resistant to neuraminidase inhibitors (NAIs), concomitant diseases of
patients, and a new pandemic virus. If the systemic procedure would be functioned, we
are able to reduce individually burden of patients with severe clinical symptoms and
leading complications and socially delay widespread of pandemic and plan for the
streamline management of pandemic documents.
Keywords: antiviral therapy, seasonal epidemic, pandemic, streamline surveillance,
the systemic procedure
1. Introduction
Influenza viruses spread seasonally and cause infection of the airway tract in humans follow-
ing severe symptoms. Influenza viruses grow and multiply among in human, swine, and avian
bodies. Influenza viruses escape human immunological protective system against influenza
viruses by changing their epitope detected by human immune cells. Annual seasonal influenza
epidemic often happened under no antiviral procedure by easy infection of influenza viruses.
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Seasonal influenza viruses affect 10–20% of human population in epidemics each year [1] and
worldwide, cause an estimated 3.5 million cases of severe illness and 250,000–500,000 death
each year [2]. Although almost infected patients with seasonal influenza viruses recover from
the disease in less than 2 weeks. On the other hand, some group of people containing young
children, adults being elder than 65 years old and compromised hosts with severe illness had
complications of influenza infection leading hospital admission [3]. Influenza viruses mutate
and change the disease severity in host when transferring from avian to swine or from avian to
human or from swine to human. A new mutant of influenza viruses is defined at the site of a
mutation and called as influenza A (H5N1), A (H7N9), and A (H1N1) pdm09 each, causing
severe affected people following many deaths [4]. Three influenza pandemics happened in the
twentieth century: in 1918–1919, 1957, and 1968 and were called as Spanish flu, Asian flu, and
Hong-Kong flu each and caused the severe disaster [4]. Especially Spanish flu brought esti-
mated 20–50 million mortality [4]. We have the inability to predict and testify the appearance
of dangerous influenza viruses to human health by the lack of rapid, affordable, highly
sensitive, and specific diagnostic tests. The appearance of a new mutation of influenza viruses
was noticed as unsuccessful treatment cases leading to life-threatening complications of influ-
enza infection in the treatment of seasonal influenza [4]. The expansion of disaster by both the
delayed use and little sharing of pre-pandemic information makes difficult in minimizing a
widespread of a new mutant infection of influenza virus [4]. So it is necessary to establish a
systemic procedure of diagnosis and treatment for patients with seasonal influenza and pan-
demic viruses in early phase of pandemic. In a first step of diagnosis of influenza virus
infection, we can use rapid diagnostic kits for influenza A/B virus and we diagnose easily
seasonal influenza infection in the outpatients. But rapid immune-chromatographic kits cannot
show the mutation of influenza virus subtypes, we cannot make a differential diagnosis
between seasonal and pandemic influenza virus by it [5]. A mutation of influenza virus sub-
types is evaluated by reverse-transcriptase polymerase chain reaction (RT-PCR) and direct
sequence of a recognition site of influenza virus subtypes [5]. This method is expensive and
time-consuming. We cannot apply this method to all outpatients with influenza virus. On the
course of clinical treatment, we need to discriminate patients with suspicious pandemic influ-
enza virus from the other patients with seasonal influenza effectively and economically. We
would discuss the feasibility and execution of this trial in the following chapters.
2. Prevention
It is not too enough to exaggerate that prevention is the most effective therapy for infectious
disease. It is desirable to establish universal most effective vaccine against influenza virus.
Vaccine effectiveness (VE) is influenced by viral subtype/lineage as well as the timing of
vaccination (early or late epidemic in a season). VE of trivalent influenza vaccine (TIV) is
assessed as from 20 to 50% in vaccine programs of several countries [6, 7]. The population rate
of people was over 80% in the Korean national immunization program but VE remains low in
the elderly adults [8]. They addressed the improvement of influenza vaccine including the
adoption of quadrivalent influenza vaccine (QIV), adjuvanted influenza vaccine, and high-dose
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influenza vaccine. Recently, WHO has been recommending QIV in 2013 and QIV has been
adopted in several countries. QIV is estimated cost-effective and cost saving to reduce the burden
of outpatient visit for influenza but 1.62 hospitalizations and 0.078 deaths per 100,000 indi-
viduals were estimated in Japan [9]. VE is often influenced by the timing between vaccination
and influenza epidemic. Early epidemic occurs seasonally before administration of vaccine
against seasonal influenza infection in people and VE is low. A mismatch of influenza viral
strains between vaccination and epidemic makes VE low. It is very difficult to overcome
influenza infection only by vaccination because of current VE and variability of influenza
virus. We need the adequate diagnosis and treatment systematically after the procedure of
adequate vaccination.
3. Therapy for patients with influenza viruses
3.1. Antiviral therapy
Adoption of neuraminidase inhibitors (NAIs) for treating patients with influenza virus
improves clinical incidences of outpatients leading hospitalization. Influenza infection is typi-
cal symptoms such as fever, headache, sore throat, cough, joints lasting, and sometimes
diarrhea and nausea. On the first step of the treatment for influenza, concomitant use of
antipyretic and mild analgesic drugs such as acetaminophen, are applied to the patients with
influenza viruses as symptomatic treatment. It is very difficult to suppress widespread of
influenza viruses without the isolation of patients within 1 or 2 weeks. On the next step of the
treatment for influenza, amantadine and rimantadine were administered to patients with
influenza A, and ribavirin was used to treat immunosuppressed patients with severe influenza
conditions [10]. These are limited in operating only against influenza A viruses and adverse
effect and resistance of virus to drugs lead to less use. On the use of these drugs, antiviral
effectiveness for alleviation of severe symptoms of patients with seasonal influenza viruses
was limited and not enough to suppress the widespread of those? On the third step of the
treatment for influenza, NAIs are administered to the patients with influenza viruses. The NA
protein is a homotetrameric glycoprotein with a stalk region and enzymatically active head.
The NA active site cleaves sialic acid at the glycol-sialic bond on the host cell as well as in
respiratory mucus, leading to spread of the virus [11–13]. NAIs act to inhibit the release of
progeny viral particles from infected host cells and have more effectiveness and less adverse
effects than amantadine and rimantadine when administered to patients with influenza viral
infection [14]. Administration of NAIs to patients is recommended within 48 h from the onset
of infection [14]. NAIs alleviate symptoms and shorten its duration bothered from typical
symptoms of influenza, especially high fever and headache without using antipyretic agents.
Four NAIs, namely oseltamivir, zanamivir, laninavir, and peramivir are available in various
countries and three measures of administration, namely oral intake, inhalation, and infusion to
vein are used [14]. Zanamivir was the first NAI to be developed and was licensed in 1999. Its
feature is poor absorption and an inhaled agent and is available in an intravenous form for
compassionate use [15]. Oseltamivir is a prodrug being developed on the basis of the structure
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of the active site of zanamivir and is activated in the liver [16]. Oseltamivir is administered
orally and sometimes intravenously in the patients not being tolerable in oral dose [17].
Peramivir is administered only as an intravenous formulation and show low oral bioavailabil-
ity [17]. It achieves very high concentration in the bloodstream and its half maximal inhibitory
concentration (IC50) for influenza viruses is lower than that of both oseltamivir and zanamivir
[18]. Laninamivir is another inhaled prodrug which is activated in the respiratory tract. One
inhalation of laninamivir is effective for patients with influenza virus because of long half-life
and high concentration within tissue [17]. Now the adequate measure for administration of
NAIs can be selected following as the patients’ condition and ages. If patients are children and
cannot intake NAIs orally or inhaler NAIs, intravenous infusion of peramivir would be
recommended [19].
3.2. Necessity of monitoring body temperature in patients without antipyretic and analgesic
drugs
Patients with seasonal influenza viruses almost have recovered from high-fever state within 1
or 2 days on the condition of no use of antipyretic drugs (Figure 1). So monitoring a patient’s
body temperature is useful to evaluate whether antiviral treatment is successful or not. We
showed the typical monitor of successful treatment of NAIs in body temperature measured by
Figure 1. Correlation between age and amount of time required to alleviate fever. Almost cases with NAIs treatment have
normal temperature within 3 days. This figure is cited from clinical effects of Oseltamivir, Zanamivir, Laninamivir, and
Peramivir on seasonal influenza infection on outpatients in Japan during the winter of 2012–2013. Takemoto et al. [57].
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the patient own (Figure 2). If treatment of NAIs fails to alleviate typical symptoms of patients
with influenza viruses within 2–3 days, complications of influenza viral infection; influenza-
associated pneumonia and encephalopathy would have to be investigated. The patient with
influenza virus type A detected by a rapid test for influenza viruses had been annoyed over
4 days from onset of the disease on the condition of administration of zanamivir (Figure 3),
and was diagnosed as influenza associated pneumonia by a close examination for further
diseases (Figure 4). The antibiotic drugs were additionally administered to the patient
(10-year-old girl) at the outpatient without antipyretic and analgesic drugs and pneumonia
was treated successfully at home as the diagnosis of pneumonia categorized as mild severity
and bacterial pneumonia following influenza viral infection. No new mutation of influenza
virus A derived from this patient was detected. Hospitalization would be recommended for
the severe pneumonia with any danger sign according to classification of pneumonia because
pneumonia is the significant cause of death in the world [20, 21]. We had experienced one case
of influenza-associated encephalopathy which had uncontrolled high fever and mild neuro-
psychiatric disorder despite of administration of oseltamivir. We sent the 6-year-old boy to the
hospital for diagnosis and treatment of influenza-associated encephalopathy and had good
information of a full recovery without death or neurologic sequela. In all, 200–300 cases of
influenza encephalopathy are reported as the result of 7% death, 17% survive with neurologic
sequel, and 76% full recovery of patients in a year in Japan [22]. If high fever and other typical
Figure 2. A pattern of body temperature of the patient with influenza virus A in the winter of 2017 is shown in a graph.
The NAI is effective for alleviation of high fever and no relapse of fever in the effective clinical course of NAI treatment is
shown. Patients with no complications and no resistant influenza viruses to NAIs show this pattern on the administration
of NAIs.
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symptoms in patients with influenza viruses continue over 3–4 days under the administration
of a NAI and no remarkable complications of influenza in patients, resistance of viruses to
antiviral drugs or new mutations for pandemic should be investigated. It is very important to
follow up patients in taking view of their body temperature from the beginning of NAI
treatment and inform reconsultation with the doctors to patients on the condition of little
amelioration from high fever of influenza infection within a few days.
3.3. NAIs were effective for influenza A (H1N1) pdm09
Pandemic of influenza A (H1N1) pdm09 was disseminated worldwide in 2009 –2010 and in
many countries severe complications of its infection, hospitalization, and death from it were
reported [23]. On the other hand, the incidence of such phenomenon was lower in a few
countries than in the other countries. WHO overviewed pandemic 2009 on October in 2009
and defined the difficulty of comparison for evaluating the difference factors between coun-
tries due to the different age classes used to present data and the use of crude number of cases
rather than rates [4]. The most burdened population of disease was occurred in younger age
group as a striking difference between pandemic (H1N1) 2009 and seasonal epidemic [24].
This difference is hypothesized the population difference exposed to 1918–1919 epidemic like
H1N1 influenza viruses between the elder generation over 65 years old and the younger
Figure 3. A pattern of body temperature of the patient with influenza virus A in the winter of 2017 is shown. High-grade
fever is prolonged and relapsed over 3 days from the onset of influenza infection. Usually NAI treatment does not need
the use of antipyretic agent for alleviation of high fever. Complications and/or viral mutations of resistant to NAIs cause
the prolongation of high fever.
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generation under 20. Compared with the rest of the population to develop severe disease, in
countries of Americas and the Pacific, disproportionate affection by influenza A (H1N1) pdm
09 might be influenced by the prevalence of underlying medical conditions and limited access
to medical care living conditions in addition to a social component and crowded living
conditions [25]. Therefore, it is necessary to establish the medical conditions against viral
infection and easy access to medical care in the worldwide for pandemic before administrating
antiviral drugs. Adequate diagnosis of influenza infection and the early intervention with
antiviral drugs (NAIs, etc.) to influenza viral infection among healthy little immunized popu-
lation are desirable. On the other hand, effectiveness of NAI treatment is suggested for reduc-
ing mortality when given to hospitalized patients with influenza A (H1N1) pdm09 and the
likelihood of requiring of hospital admission when given to population with confirmed or
suspected influenza A (H1N1) pdm09 at high risk of hospitalization [26, 27]. NAI treatment
following to rapid positive tests for influenza viruses might be effective for pandemic and
reduce mortality rate of pandemic [27]. Additionally, influenza-like illness (ILI) in pandemic
without laboratory confirmation among community patients with relatively severe influenza
infection and patients with underlying comorbidities would be recommended to be treated by
NAIs for reducing hospitalization and prevention of severity in early time (<48 h) after the
onset of illness [26, 27].
3.4. Resistance to antiviral drug among influenza viruses
Influenza virus is a negative-sense RNA virus and contains eight gene segments that encode
eleven proteins, including hemagglutinin (HA) and neuraminidase (NA) glycoprotein.
Figure 4. Chest X-ray films shows the influenza-associated pneumonia in the left lobe of the lung in the phase of pre- and
post-treatment with antibiotics. Close examination for prolongation of high fever after treatment of NAI clarified the
pneumonia in the patient with influenza virus infection in the early phase of pneumonia. A clinical treatment and follow
up the patient with influenza virus with NAI and no antipyretic agents is useful for evaluation and findings of complica-
tions and viral mutations.
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Influenza virus initiates the infection using HA to attach to sialic acid residues on the host cells
and entries the host cells using M2 to initial receptor mediated endocytosis and releases
progeny and propagate infection to other host cells using NA to cleave sialic acid residues on
the host cells [28]. Each year influenza virus develops mutations within these genes leading
antigenic drift and antigenic shift. Antigenic drift is represented by the little changed nature of
virus and causes epidemics. Antigenic shift means change of major variant of virus and
initiates a severe pandemic followed at intervals of a year or two by successive epidemics by
antigenic drift [13]. Different from antigenic drift in transmission between interspecies by
viruses, antigenic shift is the reassortment of gene segments between two different parental
viruses within the same host [29]. The most recent pandemic; influenza A (H1N1) pdm09 was
caused by a swine-origin H1N1 subtype, which originated from the sequential reassortment
events between human H3N2, swine H1N1 subtype, and avian H1N2 subtypes of North
America and Eurasian lineages [30]. Concerning to the nature of virus, many mutants of
viruses are reported. It is not completely understood in mechanism to produce the resistance
to antiviral drugs among influenza viruses. But many types of viruses being resistant to
antiviral drugs are reported [31]. Adamantanes were the first approved class of antiviral drugs
by binding M2 channel pore and blocking conductance either directly or allosterically. Conse-
quently, adamantanes inhibits the virus RNA release and influenza virus replication [32].
Mutated amino acids (L26F, V27A, A30T/V, S31N, G34E, and L38F) in M2 membrane domain
that line the channel pore (V27, A30, and G34) or are involved in the tetramer helix–helix
packing (L26, S31, and L38), lead to increase in pore size with hydrophilicity of the channel or
lead to narrow of the pore size with destabilization of helix–helix assembly. Consequently,
influenza viruses reduced susceptibility to adamantanes [33]. In 1980 epidemics, the first
detection of the resistance of influenza to adamantanes was reported [34]. The resistance of
influenza viruses to adamantanes was rare with 1–2% frequently until 2000 [35] but the rate of
resistance has dramatically risen to 27% since then [36]. From 2005 onward, the rate of the
resistance to adamantanes started to increase almost exponentially to 90.6% of the H3N2 and
the 15.2% of H1N1 global isolates [37]. Similar rates were confirmed in isolated viruses in the
USA and the resistance conferring mutation was S31N in the 90–98% of isolated H1N1 and
H3N2 subtypes [38]. Vast majority of adamantanes-resistant influenza virus subtypes (95%)
contained the S31N mutation [39, 40]. Similar to M2, influenza virus has mutated several
amino acids in or around neuraminidase active site to acquire the resistance to NAIs [41, 42].
Several in vitro and preclinical studies have found some mutations in neuraminidase; E119G/
A/D/V, R292K, and H274Y [43]. Therefore, a global Neuraminidase Inhibitor Susceptibility
Network (NISN) was established to monitor influenza virus to NAIs [44]. Unlike adamantanes
resistance, which initially emerged and was predominant in H3N2 subtypes, NAI resistance
first isolated and was spread in H1N1 subtypes [40, 45]. During the first 3 years of using NAI
from 1999 to 2002, no resistance basically was detected [43, 44]. But from 2008 to April 2009
[before the emergence of influenza A (H1N1) pdm 09], over 99% influenza viruses of the H1N1
isolated were resistant to oseltamivir but were sensitive to zanamivir and none of the H3N2
isolates were resistant to oseltamivir in the report of the Centers for Disease Control and
Prevention (CDC) in the USA [45]. Similarly in 2008–2009 season, more than 90% of the
circulating H1N1 subtypes globally were oseltamivir resistant [46, 47]. H274Y mutant was
predominantly circulating during 2008–2009 and rapid transmission of H274Y mutation in
influenza (H1N1) pdm 09 has been detected in communities with little or no previous expose
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to oseltamivir [48, 49]. Fortunately, almost of the pandemic H1N1 global isolates collected
between April 2009 and January 2010 were sensitive to NAIs, except an odd 0.7% and other
few H1N1 isolated local cases [50–54]. The NAI sensitive 2009 pandemic H1N1 subtypes
displaced the-pre-pandemic oseltamivir resistant H1N1 lineage and remains largely NAI
sensitive and is predominantly circulating at present [54, 55]. Sequential investigation of
influenza virus mutation following impairment of NAI treatment for seasonal epidemics is
useful for early detection of pandemic. There is no rapid diagnostic test for the detection of
mutation or strains available in clinical laboratories. Systemic reviews of influenza resistance
to NAIs did not reveal any difference in time for alleviate symptoms between oseltamivir-
resistant and oseltamivir-sensitive patients [56]. This conclusion is different from our data and
this difference might be dependent on the different analysis between the monitor for fever
isolated from symptoms and the monitor for all symptoms of patients including estimate
difference [57]. On the course of NAI treatment, an alleviation time for fever is not over 2–
3 days in the group of patients with seasonal influenza viruses susceptible to NAIs. Treatments
for patients with influenza viruses resistant to NAIs are considered to switch to other NAI:
oseltamivir to zanamivir or other NAIs or to combine two NAIs: oseltamivir and zanamivir or
three antiviral drugs; oseltamivir, adamantanes, and ribavirin [58]. Evaluated by the outcome
of influenza viral copy numbers at 48 h after treatment, dual therapy; zanamivir/oseltamivir is
less effectiveness than oseltamivir monotherapy [59]. Triple combination antiviral drugs
(TCAD) composed of oseltamivir, amantadine, and ribavirin impedes the selection of the
influenza virus A in vitro and clinical trials have been completed for the treatment with
immunocompromised hosts with influenza in the United States [60, 61]. For preparedness to
emergence and widespread of influenza virus variants resistant to antiviral drugs, new
antiviral agents targeting viral particles and mechanism of viral replication are desired. Poly-
merase inhibitors; T-705, VX-787, and S-033188 concerning to suppressing of replication, are
undergoing phase 2/3 clinical trials and favipiravir (T-705) is approved for the treatment of
pandemic in Japan [62] when NAIs are ineffective to pandemic and the government permit to
use. In addition to new antiviral agents, pandemic vaccine is necessary for pandemic prepared-
ness [5]. Genotypic and phenotypic assays are available in the surveillance laboratories. Geno-
typic assays are rapid and can be done without viral culture otherwise genetic resistance does
not always correlate phenotypic resistance [63]. Phenotypic assays are able to the effect of both
known and unknown resistant mutations coupled with genetic assays and provide suscepti-
bilities to antiviral drugs [64]. World Health Organization (WHO) category based for NA
inhibition assay is showed as follows: normal inhibition or susceptibility (S) (<10-fold increase
in IC50 for influenza A, <5-fold increase for influenza B), reduced inhibition (RI) (between 10-
and 100-fold increase for influenza A, between 5- and 50-fold increase for influenza B) and
highly reduced inhibition (HRI) (>100-fold increase for influenza A, and >50-fold increase for
influenza B [65]. All mutations were not definitely associated phenotypic resistance, but it is
important to assess the relevance between clinical and phenotypic resistance to NAIs.
3.5. Strategy for treatment and survey
Nevertheless of clinical effectiveness and little adverse effects of NAI treatment for seasonal
influenza infection, concerning about cost effectiveness of NAI treatment, conventional treat-
ment was adopted for influenza infection in healthy populations without rapid tests for
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influenza viruses [66]. Effectiveness on NAIs in reducing mortality and hospitalization in
patients with influenza A (H1N1) pdm09 was clarified [67]. Compared with no antiviral
treatment, diagnostic testing and oseltamivir treatment when positive in children with sea-
sonal influenza viruses is more effective and cost between $25,900 and $71,200 per quality-
adjusted life year gained (QALY), depending on the prevalence of oseltamivir resistance in
circulating viruses [68]. Oseltamivir treatment for influenza is less cost-effective than conven-
tional treatment, considering the productivity loss by the analysis of the incremental cost-
effective ratio (ICER) of oseltamivir in Japan [69]. Pandemic is consequent of unpredictable
mutations of seasonal influenza and the only measure of the first information about pandemic
is surveillance of an avian suspicious single death following cluster deaths or a report of
clinical worsening cases of fevers unknown origin following severe complications in medica-
tion. The case of family cluster of a highly pathogenic avian influenza A (H5N1) virus might
suggest for the hint of suppressing a widespread of viral infection to pandemic in Thailand in
2004 [70]. The index patient contacted with dying household chickens and 4 days later became
ill and was presented to clinic with fever, cough, and a sore throat. The 11-year-old girl got
worse in symptoms including fever and dyspnea within 5 days and was admitted for viral
pneumonia and died in a day despite of intensive care. Her mother and aunt provided bedside
care for her in the hospital for 18 h in 2 days and for 13 h in 1 day each. Her mother began to
have high fever after 3 days of unprotected nursing care for her and was admitted to a hospital
and died from pneumonia and progressive respiratory failure. Her aunt noted high fever,
myalgia, and chills after 9 days of unprotected nursing care for her and was admitted to the
distinct hospital. On the day of admission, the patient was suspected as pneumonia due to
avian influenza and received treatment with oseltamivir and instituted full isolation precau-
tions by an investigating team. Despite moderate dyspnea and hypoxia, she gradually amelio-
rated and was discharged a month later. First, a nasopharyngeal swab from the aunt was
weakly positive for influenza nucleoprotein gene and no evidence of influenza infection in
the laboratory data on tissue culture or egg inoculation. Specimens of lung obtained from the
mother’s body embalmed were positive for influenza A (H5N1) by RT-PCR at the Siriraj
hospital laboratory in Thailand and at CDC in the United States. This study suggests that the
systemic procedure of treatment for seasonal influenza is sequent to the systemic procedure of
preparedness and response for the following pandemics and is desirable. The desirable sys-
temic procedure for epidemic and pandemic is described as follow; [1] application of rapid
tests for influenza virus in diagnosis, [2] early administration of NAIs within 48 h from a onset
of influenza infection, [3] monitor for patients without antipyretic, [4] further investigation of
complications and mutations of influenza viruses under late time of alleviation for fever, [5]
adoption of other treatments for complications or hospitalization in the progression of illness,
[6] check of family member or cluster by surveillance system if possible and consultation to
public health center for the further investigation. After a new mutated influenza virus is
confirmed, the isolation of the patients and the contacts are given antiviral prophylaxis and
exposed persons are put under active surveillance and poultry in the surrounding area is
culled under the control of government. This procedure would be helpful for treatment of
seasonal influenza and the following pandemic. WHO recommend for development and
application of measures to assess the severity of every influenza epidemic [5] and this proce-
dure might be one of those? Addiction to measures to assess severity, strengthen surveillance
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technology is necessary to detect pandemic, too. There are four types of surveillance for
seasonal influenza epidemic in Japan and one of those? is (Nursery) School Absenteeism
Surveillance System ((N)SASSy) which enables real-time surveillance and informs its result to
school officials including school lengths and teachers by websites [71]. This is one of tools for
preparedness for epidemics: noticing each condition of the numbers of infected students with
influenza virus, both inter-schools and inter-cities on the closed website and sharing real-time
information for spread of epidemics around them. Open access to the website is available for
spread of epidemics except personal information, names of schools, and so on. This surveil-
lance system will be applied in pandemic as streamline surveillance in local. WHO suggests
the Global Influenza Surveillance Network (GISN) and mobilize the Global Outbreak and
Alert Response Network (GROAN) teams for information sharing [72]. WHO recommends a
close relationship and partnership with International Health Regulations 2005 (IHR) to prevent
and respond to acute public health risks worldwide [5]. Real-time surveillance and sharing of
its information are useful in domestics and international.
4. Conclusions
Seasonal influenza virus mutates in transmission of interspecies and suddenly changes both
highly lethal and transmissible from person to person. Prevention of influenza infection by
universal vaccine is desirable but are undergoing in development. Confirmation for the emer-
gence of pandemic influenza virus is only the detection of cluster infection with severe compli-
cations by the new mutated virus. Surveillance in local and global is the effective measure for it.
We can add the procedure of clinical diagnosis and treatment for seasonal influenza infection to
one of useful surveillance systems for pandemic. Adoption of NAIs and evaluation of clinical
effectiveness monitoring body temperature is the first step of surveillance of clinical treatment.
Assessment of NAI treatment insufficiency to influenza infection leads to the close examination
for the factors of patients and viral mutations as the second step. In third step, antigenic drift
and/or antigenic shift are examined on the condition of no patient’s factors and information
sharing for drug resistance and/or pandemic is necessary for administration of new antiviral
drugs and combination therapy of antiviral drugs and/or the management against pandemic. It
is difficult to predict when NAIs will not be ineffective to influenza infection due to viral
resistance to those? New antiviral drugs for influenza virus are under development and they
would change the treatment of influenza infection as NAIs changed it. If the new convenient and
rapid diagnostic test for influenza viral infection of seasonal influenza virus and pandemic virus
would be developed, it would be more useful than the clinical procedure. At present, the
systemic procedure of treatment and taking measure for seasonal influenza infection in usual
would lead to the preparedness and taking management against pandemic.
5. Future perspectives
Trial of antiviral therapy in influenza infection is progressed as in the treatment of hepatitis C
viral infection and HIV infection, too. Now in influenza virus infection, the three mechanical
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points for viral inhibition in cells are applied and new drugs are developed. New NAIs and
RNA polymerase inhibitor and the cap-dependent endonuclease inhibitor are in developed.
Recently, baloxavir marboxil (trade name Xofluza) may be used within a few months in Japan
and prevent viral replication by inhibiting the cap-dependent endonuclease activity of the viral
polymerase instead of inhibition for viral release from host cells as NAIs act [73]. It inhibits
influenza RNA viruses from hijacking the host mRNA transcription system to allow synthesis
of viral RNA. Only oral one dose is effective for amelioration from symptoms of influenza viral
infection with less adverse effects. New drugs and combinations for administration of antiviral
drugs against influenza virus would be defined following to the appearance of new mutations
concerning to drug resistance in the future. Seasonal influenza infection and pandemic would
be under controlled by the application of antiviral drugs, vaccination, and surveillance.
Acknowledgements
Thanks to Teizabruo Asai, Itsuo Ikezoe, Takako Yano, Masahiro Ichikawa, Shogo Miyagawa,
and Jun Matsumoto for supporting the clinical research for NAI treatment in 2012–2013 and
membership in the Osaka Medical Association in Japan.
Conflict of interests
The author has no competing of interests to declare.
Author details
Yuji Takemoto
Address all correspondence to: y-t1@vesta.ocn.ne.jp
Kamijo Medical Office, Izumiotsu City, Osaka Prefecture, Japan
References
[1] World Health Organization. Health Topic, Influenza [Internet]. 2018. Available from:
http://www.who.int/topics/influenza/en/ [Accessed: March 14, 2018]
[2] World Health Organization. Influenza, 25 January 2008 [Internet]. 2008. Available from:
http://www.who.int/topics/influenza/en/.index.html [Accessed: March 14, 2018]
Influenza - Therapeutics and Challenges144
[3] Memoli MJ, Athota R, Reed S, et al. The natural history of influenza infection in the
severely immunocompromised vs nonimmunocompromised hosts. Clinical Infectious
Diseases. 2014;58(2):214-224. DOI: 10.1093/cid/cit725
[4] World Health Organization. Sixty Fourth World Health Assembly Provisional Agenda Item
13.2. 5 May 2011. Report of the Review Committee on the Functioning of the International
Health Regulations in relation to Pandemic (H1N1) 2009 [Internet]. 2009. Available from:
http://apps.who.int/gb/ebwha/pdf_files/WHA64/A64_10-en.pdf [Accessed: March 14, 2018]
[5] WHO Recommendations on the Use of Rapid Testing for Influenza Diagnosis. July 2005
[Internet]. 2005. Available from: http://www.who.int/influenza/resources/documents/
RapidTestInfluenza_WebVersion.pdf [Accessed March 14, 2018]
[6] Andrew MK, Shinde V, Hatchette T, Ambrose A, Boivin G, Bowie W, et al., and on behalf
of the Public Health Agency of Canada/Canadian Institutes of Health Research Influenza
Research Network (PCIRN) Serious Outcomes Surveillance Network and the Toronto
Invasive Bacterial Diseases Network (TIBDN). Influenza vaccine effectiveness against
influenza-related hospitalization during a season with mixed outbreaks of four influenza
viruses: A test-negative case-control study in adults in Canada. BMC Infectious Disease.
BMC series-open inclusive and trusted. 2017;17:805. Published online 2017 Dec 29. DOI:
10.1186/s12879-017-2905-8
[7] Jackson ML, Phillips CH, Benoit J, Jackson LA, Gaglani M, Murthy K, HQML, Belongia EA,
Malosh R, Zimmerman R, Flannery B. Burden of medically attended influenza infection and
cases averted by vaccination United States, 2013/14 through 2015/16 influenza seasons.
Vaccine. Jan 25, 2018;36(4):467-472:S0264-410X(17)31755-3. DOI: 10.1016/j.vaccine.2017.12.014
[8] Yun JW, Noh JY, Song JY, Chun C, Kim Y, Cheong HJ. The Korean Influenza National
Immunization Program: History and present status. Infection & Chemotherapy. 2017;
49(4):247-254. DOI: 10.3947/ic.2017.49.4.247
[9] Tsuzuki S, Schwehm M, Eichner M. Simulation studies to assess the long-term effects of
Japan’s change from trivalent to quadrivalent influenza vaccination. Vaccine. 2018;36(5):
624-630. DOI: 10.1016/j.vaccine.2017.12.058
[10] Hayden FG. Prevention and treatment of influenza in immunocompromised patients. The
American Journal of Medicine. 1997;102(3, Supplement 1):55-60 ; discussion 75–76. DOI:
10.1016/S0002-9343(97)80013-7
[11] Nayak DP, Balogun RA, Yamada H, Zhou ZH, BS. Influenza virus morphogenesis and
budding. Virus Research. 2009; Aug;143:147-161. DOI: 10.1016/j.virusres.2009.05.010
[12] Colman PM, Verghese JN, Laver WG. Structure of the catalytic and antigenic sites in
influenza virus neuraminidase. Nature. 1983;303:41-44
[13] Hope-Simpson RE, Golubev DB. A new concept of the epidemic process of influenza A
virus. Epidemiology and Infection. 1987;99:5-54
Therapeutic Approach for Seasonal Influenza and Pandemic
http://dx.doi.org/10.5772/intechopen.76473
145
[14] Moscona A. Neuraminidase inhibitors for influenza. The New England Journal of Medi-
cine. 2005;353:1363-1373. DOI: 10.1056/NEJMra050740
[15] Von ItzsteinM,WuWY, Kok GB, et al. Rational design of potent sialidase-based inhibitors
of influenza virus replication. Nature. 1993;363:418-423. DOI: 10.1038/363418a0
[16] Kim CU, Lew W, Williams MA, et al. Influenza neuraminidase inhibitors possessing a
novel hydrophobic interaction in the enzyme active site: Design, synthesis, and structural
analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. Journal of
the American Chemical Society. 1997;119:681-690. DOI: 10.1021/ja963036t
[17] Samson M, Pizzorno A, Abed Y, Boivin G. Influenza virus resistance to neuraminidase
Inhibitors. Antiviral Research. 2013;98(2):174-185. DOI: 10.1016/j.antiviral.2013.03.014
[18] Chairat K, Taming J, White NJ, et al. Pharmacokinetic properties of anti- influenza neur-
aminidase inhibitors. Journal of Clinical Pharmacology. 2013;53(2):119-139. DOI: 10.1177/
0091270012440280
[19] Hikita T, Hikita H, Hikita F, Hikita N, Hikita S. Clinical effectiveness of peramivir in
comparison with other neuraminidase inhibitors in pediatric influenza patients. Interna-
tional Journal of Pediatrics. 2012;2012:8341812. DOI: 10.1155/2012/834181
[20] Mackenzie G. The definition and classification of pneumonia. Pneumonia. 2016;8:14.
[Internet]. Available from: https://doi.org/10.1186/s41479-016-0012-z [Accessed: March
14, 2018]
[21] WHO Library Cataloguing-in-Publication Data. Revised WHO Classification and Treat-
ment of Pneumonia in Children at Health Facilities: Evidence Summaries 1. Pneumonia-
Drug Therapy 2. Child 3. Health Facilities 4. Guideline I. World Health Organization. ISBN:
9789241507813 (NLM Classification: WA320) [Internet]. 2014. Available from: http://apps.
who.int/iris/bitstream/10665/137319/1/9789241507813_eng.pdf [Accessed: March 14, 2018]
[22] Mizuguchi M. Influenza encephalopathy and related neuropsychiatric syndromes. Influ-
enza and Other Respiratory Viruses;7(Suppl. 3):67-71. DOI: 10.1111/irv.12177. [Internet].
Available from: www.influenzajournal.com [Accessed: March 14, 2018]
[23] World Health Organization. Disease Outbreak News: Pandemic (H1N1)2009-UPDATE
112–6 Aug 2010 [Internet]. Available from: http://www.who.int/csr/don/2010 08 06/en/
index/.html [Accessed: March 14, 2018]
[24] Bush R. Influenza forensics. In: Budolwe B et al., editors. Microbial Forensics. 2nd ed.
London: Academic Press; 2011. pp. 109-135. [Internet]. Available from: http://www.
sciencedirect.com/science/article/pii/B9780123820068000086 [Accessed: March 14, 2018]
[25] Writing Committee of theWHOConsultation on Clinical Aspects of Pandemic (H1N1) 2009
Influenza. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. The New
England Journal of Medicine. 2010;362:1078-1719. DOI: 10.1056/NEJMra1000494PMID.2044
5182. [Internet] 2010. Available from: http://www.nejm.org/doi/full/10.1056/NEJMra100044
9 [Accessed: March 14, 2018]
Influenza - Therapeutics and Challenges146
[26] Venkatesan S, Myles PR, Bee JL, Muthuri SG, Masri MA, Andrew N, Bantar C, et al.
Impact of outpatient neuraminidase inhibitor treatment in patients infected with influ-
enza A (H1N1)pdm09 at high risk of hospitalization: An individual participant data
metaanalysis. Clinical Infectious Diseases. 2017;64(10):1328-1334 . Published Online 2017
Feb 12. DOI: 10.1093/cid/cix127
[27] Louis JK, Yang S, Acosta M, Yen C, Samuel MC, Schechter R, Guevara H, Ueki TM.
Treatment with neuraminidase inhibitors for critically ill patients with influenza A
(H1N1) pdm09. Clinical Infectious Diseases. 2012;55(9):1198-1204
[28] Stouffer AL, Acharya R, Salom D, et al. Structural basis for the function and inhibition of
an influenza virus proton channel. Nature. 2008;451(7178):596-599
[29] Worobey M, Han GZ, Rambaut A. Genesis and pathogenesis of the 1918 pandemic H1N1
influenza A virus. Proceedings of the National Academy of Sciences of the United States of
America. 2014;111:8107-8112
[30] Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin
H1N1 influenza virus. Nature. 2009;459:931-939
[31] Hussain M, Galvin HD, Haw TY, Nutsford AN, Husain M. Drug resistance in influenza A
virus: The epidemiology and management infect. Drug Resistance. 2017;10:121-134.
Published online 2017 Apr. 20. DOI: 10.2147/DR.S105473
[32] Schnell JR, Chou JJ. Structure and mechanism of the M2 proton channel of influenza A
virus. Nature. 2008;451:591-595
[33] Cady SD, Schmidt-Rohr K, Wang J, Soto CS, Degrado WF, Hong M. Structure of the
amantadine binding site of influenza M2 proton channels in lipid bilayers. Nature. 2010;
463:689-692
[34] Heider H, Adamczyk B, Presber HW, Schroeder C, Feldblum R, Indulen MK. Occurrence
of amantadine-and rimantadine-resistant influenza A virus strains during the 1980 epi-
demic. Acta Virologica. 1981;25:395-400
[35] Suzuki H, Saito R, Masuda H, Oshitani H, Sato M, Sato I. Emergence of amantadine-
resistant influenza A viruses: Epidemiological study. Journal of Infection and Chemother-
apy. 2003;9:195-200
[36] Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A
(H3N2) viruses isolated worldwide from 1994 to 2005: A cause for concern. Lancet. 2005;
366:1175-1181
[37] Dong G, Peng C, Luo J, et al. Adamantane-resistant influenza A viruses in the world (1902–
2013): Frequency and distribution of M2 gene mutations. PLoS One. 2015;10:e0119115
[38] Centers for Disease Control and Prevention (CDC). High levels of adamantane resistance
among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents—
United States, 2005–06 influenza season. MMWR. Morbidity and Mortality Weekly
Therapeutic Approach for Seasonal Influenza and Pandemic
http://dx.doi.org/10.5772/intechopen.76473
147
Report. 2006;55:44-46. [Internet]. 2006. Available from: https://www.cdc.gov/mmwr/pre-
view/mmwrhtml/mm5502a7.htm [Accessed: March 14, 2018]
[39] Garcia V, Aris-Brosou S. Comparative dynamics and distribution of influenza drug resis-
tance acquisition to protein M2 and neuraminidase inhibitors. Molecular Biology and
Evolution. 2014;31:355-363
[40] Collins PJ, Haire LF, Lin YP, et al. Structural basis for oseltamivir resistance of influenza
viruses. Vaccine. 2009;27:6317-6323
[41] Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibi-
tor resistance among human influenza A and B viruses circulating worldwide from 2004
to 2008. Antimicrobial Agents and Chemotherapy. 2008;52:3284-3292
[42] Zambon M, Hayden FG. Global neuraminidase inhibitor susceptibility network. Position
statement: Global neuraminidase inhibitor susceptibility network. Antiviral Research.
2001;49:147-156
[43] Monto AS, McKimm-Breschkin JL, Macken C, et al. Detection of influenza viruses resis-
tant to neuraminidase inhibitors in global surveillance during the first 3 years of their use.
Antimicrobial Agents and Chemotherapy. 2006;50:2395-2402
[44] Hurt AC, Barr IG, Hartel G, Hampson AW. Susceptibility of human influenza viruses
from Australia and South East Asia to the neuraminidase inhibitors zanamivir and
oseltamivir. Antiviral Research. 2004;62:37-45
[45] Dharan NJ, Gubareva LV, Meyer JJ, et al. Infections with oseltamivir-resistant influenza A
(H1N1) virus in the United States. Journal of the American Medical Association. 2009;301:
1034-1041
[46] Baranovich T, Saito R, Suzuki Y, et al. Emergence of H274Y oseltamivir-resistant A(H1N1)
influenza viruses in Japan during the 2008–2009 season. Journal of Clinical Virology. 2010;
47:23-28
[47] Hurt AC, Ernest J, Deng YM, et al. Emergence and spread of oseltamivir-resistant A(H1N1)
influenza viruses in Oceania, South East Asia and South Africa. Antiviral Research. 2009;
83(1):90-93
[48] Takashita E, Kiso M, Fujisaki S, et al. Characterization of a large cluster of influenza A
(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013–2014
influenza season in Japan. Antimicrobial Agents and Chemotherapy. 2015;59:2607-2617
[49] Hurt AC, Hardie K, Wilson NJ, et al. Characteristics of a widespread community cluster of
H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. The Journal of Infec-
tious Diseases. 2012;206:148-157
[50] Gubareva LV, Trujillo AA, Okomo-AdhiamboM, et al. Comprehensive assessment of 2009
pandemic influenza A (H1N1) virus drug susceptibility in vitro. Antiviral Therapy. 2010;
15:1151-1159
Influenza - Therapeutics and Challenges148
[51] Leung TW, Tai AL, Cheng PK, et al. Detection of an oseltamivir-resistant pandemic
influenza A/H1N1 virus in Hong Kong. Journal of Clinical Virology. 2009;46(3):298-299
[52] Centers for Disease Control and Prevention (CDC). Oseltamivir-resistant 2009 pandemic
influenza A (H1N1) virus infection in two summer campers receiving prophylaxis—
North Carolina, 2009. MMWR. Morbidity and Mortality Weekly Report. 2009;58:969-972
[53] Centers for Disease Control and Prevention (CDC). Oseltamivir-resistant novel influenza
A (H1N1) virus infection in two immunosuppressed patients—Seattle, Washington, 2009.
MMWR. Morbidity and Mortality Weekly Report. 2009;58:893-896
[54] Dapat C, Kondo H, Dapat IC, et al. Neuraminidase inhibitor susceptibility profile of
pandemic and seasonal influenza viruses during the 2009–2010 and 2010–2011 influenza
seasons in Japan. Antiviral Research. 2013;99:261-269
[55] Hurt AC, Chotpitayasunondh T, Cox NJ, et al. Antiviral resistance during the 2009 influ-
enza A H1N1 pandemic: Public health, laboratory, and clinical perspectives. The Lancet
Infectious Diseases. 2012;12(3):240-248
[56] Thorlund K, Awad T, Boivin G, Thabane L. Systematic review of influenza resistance to
the neuraminidase inhibitors. BMC Infectious Diseases. 2011;134. DOI: 10.1186/1471-2334-
11-134
[57] Takemoto Y, Asai T, Ikeszoe I, Yano T, Ichikawa M, Miyagawa S, Matsumoto J. Clinical
effects of oseltamivir, zabamivir, laninamivir and peramivir on seasonal influenza infec-
tion in outpatients in Japan during the winter 2012–2013. Chemotherapy. 2013;59:373-378
[58] Kamali A, Holodniy M. Influenza treatment and prophylaxis with neuraminidase inhibi-
tors: A review. Infection and Drug Resistance. 2013;6:187-198. DOI: 10.2147/IDR.S36601
[59] Dual X, van der Werf S, Blanchon T, et al. Efficacy of oseltamivir-zanamivir combination
compared to each monotherapy for seasonal influenza: A randamaized placebo-
controlled trial. PLoS Medicine. 2010;7(11):e100032
[60] Hoops JD Driebe EM, Kelley E, et al. Triple combination antiviral drug (TACD) composed
of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influ-
enza A virus. PLoS One. 2011;6(12):E29778
[61] Fred Hutchinson Cancer Research Center. TACD vsMonotherapy for Influenza A in Immu-
nocompromised Patients. Available from: http://clinicaltrials.gov/show/NCT00867139.
NLMidentifier:NCT00867139
[62] Fukuda Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozai K, Nomura N, Egawa H,
Minami S, Watanabe Y, Narita H, Shiraki K. In vitro and in vivo activities of anti-influenza
virus compound T-705. Antimicrobial Agents and Chemotherapy. 2002:977-981
[63] Okumo-Adhiambo M, Sheu TG, Gubareva LV. Assay for monitoring susceptibility of
influenza viruses to neuraminidase inhibitors. Influenza and Other Respiratory Viruses.
2013;7:44-49
Therapeutic Approach for Seasonal Influenza and Pandemic
http://dx.doi.org/10.5772/intechopen.76473
149
[64] Gubareva LV, Webster RG, Hayden FG. Detection of influenza virus resistance to neur-
aminidase inhibitors by the enzyme inhibition assay. Antiviral Research. 2002;53:47-61
[65] World Health Organization [Internet]. Available from: http://www.who.int/influenza/
gisrs_laboratory/antiviral_susceptibility/nai_overview/en/ [Accessed: March 14, 2018]
[66] Allan J, AlexanderW, Sutton J, Cooper NJ, Turner DA, Abraham KR, Brennan A, Nicolson
KG. Cost-effectiveness and value of information analyses of neuraminidase inhibitors for
the treatment of influenza. Value in Health. 2008;11(2):160-171. DOI: 10.1111/j.1524-4733.
2007.00241.x
[67] Muthuri SG, Venkatesan S, Myles PR, Bee L, et al. Effectiveness of neuraminidase inhibi-
tors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09
virus infection: A meta-analysis of individual participant data. The Lancet Respiratory
Medicine. 2014;2:395-404. DOI: 10.1016/S2213-2600(14)70041-4
[68] Lavelle TA, Uyeki TM, Prosser LA. Cost effectiveness of oseltamivir treatment for children
with uncomplicated seasonal influenza. The Journal of Pediatrics. 2012;160(1):67-73
[69] Nagase H, Moriwaki K, Kamae M, Yanagisawa S, Kamae I. Cost-effectiveness analysis of
oseltamivir for influenza treatment considering the virus emerging resistant to the drug in
Japan. Value in Health. 2009;12(Supplements 3):62-65
[70] Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, Puthavathana P,
Uiprasertkul M, Boonnak K, Pittayawonganon C, Cox NJ, Zaki SR, Thawatsupha P,
Chittaganpitch M, Khontong R, Simmerman JM, Chunsutthiwat S. Probable person-to-
person transmission of avian influenza A (H5N1). The New England Journal of Medicine.
2005;352(4):333-340. DOI: 10.1056/NEMJMoa044021
[71] Shimatani N, Sugishita Y, Sugawara T, Nakamura Y, Ohkusa Y, Yamagishi T, et al.
Enhanced surveillance for the sports festival in Tokyo 2013: Preparation for the Tokyo
2020 Olympic and Paralympic games. Japanese Journal of Infectious Diseases. 2015;68:
288-295
[72] Heymann D, Kindhausser M, Rodier G. Coordinating the global response. In: Sars: How a
Global Epidemic was Stopped. Manila: WHO Regional Office for the Western Pacific;
2006. pp. 49-55. DOI: 10.2471/BLT.07.032763
[73] A Study of S-033188 (Baloxavir Marboxil) Compared with Placebo or Oseltamivir in
Otherwise Healthy Patients with Influenza (Capstone 1) [Internet]. 2018. Available from:
https://clinicaltrials.gov/ct2/show/NCT02954354 [Accessed: March 14, 2018]
Influenza - Therapeutics and Challenges150
